Serum Asymmetric Dimethylarginine, Nitrate, Vitamin B12, and Homocysteine Levels in Individuals with Pulmonary Embolism

We aimed to analyze the pre- and posttreatment serum asymmetric dimethylarginine (ADMA), nitrate (NO3), vitamin B12and homocysteine levels in pulmonary embolism (PTE) patients and to determine the prognostic value of these variables in predicting chronic thromboembolic pulmonary hypertension (CTEPH). This study was conducted in 64 patients. The patients were classified into the two groups: patients with normal pulmonary artery pressure (PAP) (group I) and patients with high PAP with persistent lung perfusion defects or who died at the end of 3 months of therapy (group II). We found statistically significant differences between two groups with respect to the partial oxygen pressure, the oxygen saturation, and the PAP, but there was no difference between the two groups with respect to the pretreatment ADMA, NO3, or homocysteine levels. The vitamin B12levels were higher in group II. The NO3levels increased and the ADMA and vitamin B12levels decreased with treatment in both groups. These results suggest that these parameters are not predictive of the development of CTEPH.

Download Full-text

COMPARATIVE EVALUATION OF TREATMENT OF ACUTE PULMONARY EMBOLISM (ACCORDING TO DATA CLINICAL HOSPITAL OF ALMATY #7)

Vestnik ◽

10.53065/kaznmu.2021.86.40.011 ◽

2021 ◽

pp. 57-61

Author(s):

С.М. Анартаев ◽

О. Тайманулы ◽

Д.М. Кайралиев ◽

К.А. Ергешов ◽

Е.Б. Ибадуллаев ◽

...

Keyword(s):

Pulmonary Embolism ◽

Anticoagulant Therapy ◽

Comparative Evaluation ◽

Acute Pulmonary Embolism ◽

Therapy Group ◽

Heparin Group ◽

Group Iii ◽

Group I ◽

Complex Therapy ◽

Acute Pe

В статье представлены результаты сравнительного анализа 50 больных тромбоэмболии легочной артерии (ТЭЛА), которые по способу лечения были разделены на 3 группы: I группа - с антикоагулянтной терапией (гепарин). II группа - с селективной катетерной тромболитической (альтеплаза) и антикоагулянтной терапией. III группа - с катетерной аспирационной тромбоэкстракцией; Установлено, что на фоне комплексной терапии, включающую тромболитическую и антикоагулянтную терапии наблюдалась лучшая выживаемость пациентов с острой ТЭЛА. The article presents results of a comparative analysis of 50 patients with pulmonary embolism (PE), which were divided into 3 groups according to the method of treatment: Group I - with anticoagulant therapy (heparin); Group II - with catheter thrombolytic (alteplase) and anticoagulant therapy. Group III - with catheter embolectomy (aspiration thromboextraction); It was found against the background of complex therapy, including thrombolytic and anticoagulant therapy, there was a better survival rate for patients with acute PE.

Download Full-text

Fibrinogen AAlpha-Thr312ala Polymorphism Is Comparably Associated With Acute Pulmonary Embolism And With Chronic Thromboembolic Pulmonary Hypertension

10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2418 ◽

2011 ◽

Author(s):

Cynthia W. Baffi ◽

Timothy A. Morris

Keyword(s):

Pulmonary Embolism ◽

Pulmonary Hypertension ◽

Acute Pulmonary Embolism ◽

Chronic Thromboembolic Pulmonary Hypertension ◽

Thromboembolic Pulmonary Hypertension

Download Full-text

Course of epilepsy in patients with clinical manifestations of cranio-cerebral imbalance and a low scf-cranial index

Epilepsia and paroxyzmal conditions ◽

10.17749/2077-8333.2018.10.3.038-043 ◽

2018 ◽

Vol 10 (3) ◽

pp. 38-43

Author(s):

V. I. Larkin ◽

N. S. Stelmakh

Keyword(s):

Head Circumference ◽

Therapy Group ◽

Laboratory Data ◽

Clinical Manifestations ◽

Epileptic Seizures ◽

Occurrence Rate ◽

Group I ◽

Cranial Index ◽

Seizure Rate ◽

Group Ii

The aim of the study was to assess the course of epilepsy in patients with signs of cranio-cerebral imbalance with a low CSF-cranial index.Materials and methods. We conducted a prospective analysis of clinical, instrumental and laboratory data from the case histories of 78 patients with epileptic seizures (cryptogenic epilepsy). Group I included 36 patients with normal reserve CSF volumes and physiological values of the CSF-cranial index; these patients received standard multicomponent therapy. Group II was comprised of 42 patients with abnormally small reserve CSF spaces and a lower than normal CSF-cranial index; patients in group II received the same treatment as did patients in group I.Results. We found a moderate correlation between the head circumference and the values of the CSF-cranial index. A strong correlation between the seizure occurrence rate and the values of the CSF-cranial index was also found (R=0.32, p=0.0043); the seizure rate correlation with the head circumference was less obvious (R=0.11, p=0.037). Most of the patients in group I had bilateral seizures, whereas in patients of group II the seizures were of a mixed character.Conclusion. The results of this clinical study suggest that the course of epilepsy in patients with a low CSF-cranial index is determined by the severity of anatomical reduction in the CSF dynamics; in most cases of a low CSF-cranial index, the course of epilepsy is severe. These findings should be considered at the starting and the later stages of antiepileptic therapy.

Download Full-text

Asymmetric Dimethylarginine and Endothelial Progenitor Cells After Renal Transplantation: the Effect of Exercise Training

Physiological Research ◽

10.33549/physiolres.932886 ◽

2014 ◽

pp. S411-S417

Author(s):

V. TEPLAN ◽

I. KRÁLOVÁ LESNÁ ◽

J. PIŤHA ◽

A. MAHROVÁ ◽

J. RACEK ◽

...

Keyword(s):

Renal Transplantation ◽

Progenitor Cells ◽

Endothelial Progenitor Cells ◽

Asymmetric Dimethylarginine ◽

Exercise Program ◽

Cardiovascular Complications ◽

Hla Typing ◽

Endothelial Progenitor ◽

Group I ◽

Group Ii

Level of asymmetric dimethylarginine (ADMA) is elevated and endothelial progenitor cells (EPC) and stem cells (SC) are decreased in patients undergoing renal transplantation (Tx) and may contribute to cardiovascular complications. We tested the hypothesis that ADMA, EPC and SC can be influenced with regular physical exercise early after Tx. Blood samples of ADMA, EPC, SC, adipocytokines and metabolic parameters were randomly obtained from 50 transplant patients before and 6 months after exercise program (Group I). Fifty age, sex, HLA typing, duration of dialysis and immunosupression regimen-matched non exercising transplant were examined as controls (Group II). After 6 months, in Group I ADMA decreased (3.50±0.45 vs 2.11±0.35 μmol/l, P<0.01) and was lower comparing to Group II (P<0.01), SC and EPC also decreased (2816±600 vs 2071±480 cells/ml resp. 194±87 to 125±67 cells/ml, P<0.02). Next changes in Group I: adiponectin (P<0.01), leptin (P<0.01), resistin (P<0.02). Visfatin, blood lipids, HbA1c, insulin and blood pressure were also influenced by training program (P<0.05).

Download Full-text

Acute Pulmonary Embolism

10.2310/im.1632 ◽

2019 ◽

Author(s):

Brett J Carroll ◽

Eric A Secemsky

Keyword(s):

Pulmonary Embolism ◽

Diagnostic Imaging ◽

Risk Stratification ◽

Chronic Thromboembolic Pulmonary Hypertension ◽

Integrated Approach ◽

Initial Management ◽

Right Ventricular Strain ◽

Thromboembolic Pulmonary Hypertension ◽

Short And Long Term

Pulmonary embolism (PE) is a frequently encountered clinical condition with both short- and long-term adverse consequences. An integrated approach to diagnosis is important to maximize early diagnosis but also to minimize the unnecessary utilization of diagnostic imaging. Comprehensive risk stratification with clinical features and assessment of right ventricular strain by diagnostic imaging and cardiac biomarker results are essential to guide initial management decisions. There is a growing treatment arsenal for acute PE, including increased anticoagulation and advanced therapeutic options such as catheter-based therapy. Despite such advances, mortality remains high, particularly among those who present critically ill with PE, and long-term physical and psychological effects can persist in many patients for years after the initial diagnosis. This review contains 7 figures, 6 tables, and 69 references. Key Words: anticoagulation, catheter-directed therapy, chronic thromboembolic pulmonary hypertension pulmonary embolism, computed tomography, echocardiography, fibrinolysis, risk stratification, venous thromboembolism

Download Full-text

Risk Factors and Epidemiology of Pulmonary Embolism

DeckerMed Surgery ◽

10.2310/surg.1645 ◽

2020 ◽

Author(s):

Aaron B Waxman ◽

Aaron W Aday

Keyword(s):

United States ◽

Risk Factors ◽

Pulmonary Embolism ◽

Recurrent Events ◽

Hormone Replacement ◽

Chronic Thromboembolic Pulmonary Hypertension ◽

The United States ◽

Vein Thrombosis ◽

Thromboembolic Pulmonary Hypertension ◽

Deep Vein

More than 200,000 individuals are hospitalized with an acute pulmonary embolism in the United States annually. Despite advances in diagnosis and treatment, pulmonary embolism accounts for nearly 1% of all cardiovascular-related deaths each year in the United States alone. Those who survive an acute episode remain at a risk of recurrent events as well as ongoing dyspnea, reduced quality of life, and chronic thromboembolic pulmonary hypertension. Recognized risk factors for pulmonary embolism include advanced age, obesity, smoking, malignancy, immobilization from any cause, pregnancy and the postpartum period, oral contraceptives, and hormone replacement therapy. Numerous heritable and acquired thrombophilias increase the risk of pulmonary embolism. Additionally, inflammation and autoimmune disorders are increasingly recognized as potent risk factors for pulmonary embolism. This review contains 3 figures, 6 tables, 54 references. Key Words: anticoagulation, deep vein thrombosis, epidemiology, genetics, inflammation, malignancy, pulmonary embolism, thrombosis, venous thromboembolism

Download Full-text

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.1995.13.10.2575 ◽

1995 ◽

Vol 13 (10) ◽

pp. 2575-2581 ◽

Cited By ~ 131

Author(s):

A D Seidman ◽

A Tiersten ◽

C Hudis ◽

M Gollub ◽

S Barrett ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Peak Plasma ◽

Therapy Group ◽

Metastatic Breast ◽

Salvage Chemotherapy ◽

Median Response ◽

Visual Symptoms ◽

Group I ◽

Group Ii

PURPOSE To evaluate the efficacy and safety of paclitaxel administered by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. PATIENTS AND METHODS Forty-nine patients with metastatic breast cancer received paclitaxel via 3-hour intravenous infusion after standard premedication. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not used, and chemotherapy was cycled every 3 weeks. For 25 patients who received paclitaxel as initial therapy (group I), the starting dose was 250 mg/m2. Twenty-four patients who had received two or more prior regimens, including an anthracycline (group II), started at 175 mg/m2. Paclitaxel pharmacokinetics were evaluated in 23 patients in group I. RESULTS Grade 3 and 4 toxicities included (groups I/II) neutropenia (36%/33%), thrombocytopenia (0%/8%), anemia (0%/13%), neuropathy (8%/0%), arthralgia/myalgia (16%/4%), and mucositis (4%/4%). No significant hypersensitivity-type reactions or cardiac arrhythmias were seen. Six patients who received paclitaxel at > or = 250 mg/m2 experienced transient photopsia, without apparent chronic neuro-ophthalmologic sequelae. The mean peak plasma paclitaxel concentration was 5.87 mumol/L (range, 1.99 to 7.89) for these patients, and 6.08 mumol/L (range, 0.81 to 13.81) for 17 of 19 patients who did not experience visual symptoms. In 25 assessable patients in group I at a median follow-up time of 12 months, one complete response (CR) and seven partial responses (PRs) have been observed, for a total response rate of 32% (95% confidence interval [CI], 15% to 53%). In group II, five PRs were noted in 24 assessable patients (20.8%; 95% CI, 7% to 42%). Median response durations were 7 months for group I and 4 months for group II. CONCLUSION Paclitaxel via 3-hour infusion, without prophylactic G-CSF, is active and safe as initial and subsequent therapy for metastatic breast cancer. The transient visual symptoms noted at higher doses seem unrelated to peak plasma paclitaxel concentration. Further studies that compare 3- and 24 hour (or other) infusion schedules are necessary to determine the optimal administration of paclitaxel in metastatic breast cancer.

Download Full-text